4-Chlordehydromethyltestosterone

4-Chlorodehydromethyltestosterone (CDMT), also known as Oral Turinabol, is classified as an anabolic-androgenic steroid (AAS). It serves as the 4-chloro-substituted derivative of metandienone (dehydromethyltestosterone)¹². Here's a concise breakdown of CDMT:

Medical Application:

CDMT emerged as the inaugural product of Jenapharm, an East German pharmaceutical entity, and received patent protection in 1961. Chemist Albert Stachowiak conceived the innovative idea of amalgamating the structures of 4-chlorotestosterone (clostebol) and metandienone, ushering in a novel dissociation of anabolic and androgenic effects post-oral administration. Clinical utilization commenced in 1965 and endured until 1994, when production ceased¹.

Sports Doping:

CDMT played a pivotal role in a clandestine doping initiative, famously known as State Plan Topic 14.25, wherein approximately ten thousand East German athletes were surreptitiously administered the steroid. Many athletes remained oblivious to the true nature of the "vitamins" they were coerced to ingest. This covert program spanned from approximately 1968 until the dissolution of the German Democratic Republic in 1989. The extensive reach of this operation came to light in the 1990s, uncovering numerous instances of medal victories and record-breaking performances. Subsequent investigations prompted the International Olympic Committee to reanalyze samples from the Beijing 2008 and London 2012 Olympic Games, revealing traces of long-lasting CDMT metabolites. Notably, weightlifters and sprinters, predominantly from Russia, Ukraine, and Belarus, were identified as users of CDMT¹.

It's crucial to acknowledge that the usage of CDMT lacked medical sanction, and its associated risks should be thoroughly evaluated. Always prioritize health and well-being when contemplating the use of performance-enhancing substances.